博晖创新：控股子公司人凝血因子Ⅷ获得药品注册证书

Core Viewpoint - The announcement indicates that Bohui Innovation's subsidiary has received regulatory approval for a new drug, which is a significant milestone for the company in the biopharmaceutical sector [1] Group 1: Company Developments - Bohui Innovation's subsidiary, Hebei Bohui, has developed a drug called "Human Coagulation Factor VIII" [1] - The drug has been granted a drug registration certificate by the National Medical Products Administration, with the approval number Guoyao Zhunzi S20250068 [1] - The product is specified in a dosage of 200 IU per bottle and is intended for the treatment of Hemophilia A and acquired Factor VIII deficiency-related bleeding [1]